Analysts See $0.90 EPS for ANI Pharmaceuticals Inc (ANIP)

October 7, 2017 - By Linda Rogers

 Analysts See $0.90 EPS for ANI Pharmaceuticals Inc (ANIP)
Investors sentiment decreased to 1.06 in 2017 Q2. Its down 0.34, from 1.4 in 2017Q1. It fall, as 20 investors sold ANI Pharmaceuticals Inc shares while 42 reduced holdings. 17 funds opened positions while 49 raised stakes. 6.39 million shares or 4.42% more from 6.12 million shares in 2017Q1 were reported.
Mason Street Advisors Ltd Limited Liability Company owns 1,980 shares. Geode Capital Mgmt Lc has invested 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Citadel Advsrs Ltd Co invested in 0% or 20,716 shares. Farmers & Merchants reported 131 shares. Rhumbline Advisers owns 15,992 shares. Moreover, Stevens Capital Ltd Partnership has 0.01% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Ameriprise Finance Inc stated it has 54,205 shares or 0% of all its holdings. Cadence Cap Mngmt Ltd Liability invested in 6,397 shares or 0.02% of the stock. Kbc Gp Nv holds 0.01% or 16,057 shares in its portfolio. Ativo Cap Management Ltd Liability Corp has invested 0.33% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Blackrock owns 1.16 million shares or 0% of their US portfolio. Glenmede Na stated it has 0.09% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 235 shares in its portfolio. Endurant Cap Mngmt L P reported 15,600 shares. Moreover, Perceptive Advsrs Ltd Liability has 0.3% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Analysts await ANI Pharmaceuticals Inc (NASDAQ:ANIP) to report earnings on November, 2. They expect $0.90 earnings per share, down 11.76 % or $0.12 from last year’s $1.02 per share. ANIP’s profit will be $10.53M for 14.90 P/E if the $0.90 EPS becomes a reality. After $0.88 actual earnings per share reported by ANI Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 2.27 % EPS growth. The stock increased 0.51% or $0.27 on October 6, reaching $53.64. About 41,880 shares traded. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has declined 0.02% since October 8, 2016 and is downtrending. It has underperformed by 16.72% the S&P500.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. ANI Pharma had 16 analyst reports since July 31, 2015 according to SRatingsIntel. On Friday, November 13 the stock rating was initiated by Standpoint Research with “Buy”. Oppenheimer maintained ANI Pharmaceuticals Inc (NASDAQ:ANIP) rating on Friday, August 5. Oppenheimer has “Outperform” rating and $71 target. On Wednesday, August 9 the stock rating was maintained by Canaccord Genuity with “Buy”. TH Capital maintained ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Tuesday, August 4 with “Neutral” rating. Standpoint Research downgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Tuesday, May 24 to “Hold” rating. The firm has “Buy” rating given on Wednesday, September 2 by TheStreet. The rating was downgraded by TH Capital to “Neutral” on Wednesday, February 22. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Buy” rating by Roth Capital on Monday, September 28. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Strong Buy” rating given on Thursday, June 23 by Raymond James. TH Capital upgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Monday, September 28 to “Buy” rating.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The company has market cap of $627.44 million. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It has a 119.03 P/E ratio. The Firm focuses on areas, including controlled substances, anti-cancer , hormones and steroids, and complex formulations.

More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: which released: “ANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of …” on August 17, 2017, also with their article: “ANI Pharmaceuticals’ (ANIP) CEO Arthur Przybyl on Q2 2017 Results – Earnings …” published on August 04, 2017, published: “ANI Pharmaceuticals Acquires Inderal® XL and InnoPran XL®” on February 24, 2017. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: and their article: “ANI Pharmaceuticals Revs The Throttle Of Corticotropin Candidate” published on March 09, 2017 as well as‘s news article titled: “ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate …” with publication date: June 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts

Twitter Auto Publish Powered By :